tirolizumab + S-1 + oxaliplatin + capecitabine

This is a combination regimen consisting of four agents: - **Tirolizumab** (likely a typographical or transliteration variant of itolizumab, an anti-CD6 monoclonal antibody), presumed to be an immunotherapy targeting T-cell activation via the CD6 pathway. - **S-1**, an oral fluoropyrimidine derivative combining tegafur (a prodrug of 5-fluorouracil), gimeracil, and oteracil, used as a chemotherapy agent primarily in gastrointestinal cancers. It inhibits thymidylate synthase and disrupts DNA synthesis. - **Oxaliplatin**, a platinum-based chemotherapeutic that forms DNA crosslinks and inhibits DNA replication and transcription. - **Capecitabine**, an oral prodrug converted to 5-fluorouracil in vivo, inhibiting thymidylate synthase and interfering with DNA synthesis. The combination is experimental; such regimens are typically investigated for synergistic antitumor effects by combining immunomodulation with cytotoxic chemotherapy. The primary indications would likely be solid tumors where these agents have individual or combined activity.